{{Rsnum
|rsid=1402467
|Gene=SULT1C4
|Chromosome=2
|position=108378352
|Orientation=plus
|GMAF=0.3554
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=SULT1C4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 63.1 | 35.4 | 1.5
| HCB | 93.3 | 6.7 | 0.0
| JPT | 70.5 | 22.7 | 6.8
| YRI | 0.0 | 12.7 | 87.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 93.3 | 6.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1402467
|Name_s=SULT1C2:rs1402467 C>G; NM_006588.2:c.15C>G; NP_006579.2:p.Asp5Glu
|Gene_s=SULT1C4
|Feature=Exon/NonSyn
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: G Phenotype: The SULT1C2: rs1402467 G variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0083 Type of association: PD; CO
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111535
}}

{{GET Evidence
|gene=SULT1C4
|aa_change=Asp5Glu
|aa_change_short=D5E
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1402467
|overall_frequency_n=4616
|overall_frequency_d=10758
|overall_frequency=0.429076
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=-2
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}